Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes

JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models

(2019) Manish R. Patel et al.   CANCER GENE THERAPY

Interaction between MUC1 and STAT1 drives IFITM1 overexpression in aromatase inhibitor-resistant breast cancer cells and mediates estrogen-induced apoptosis

(2019) Taylor E Escher et al.   MOLECULAR CANCER RESEARCH

Ruxolitinib for Therapy of Graft-versus-Host Disease

(2019) Thomas Neumann et al.   Biomed Research International

Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters

(2018) Marco Del Giudice et al.   BRAIN BEHAVIOR AND IMMUNITY

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation

(2018) Joyce O’Shaughnessy et al.   BREAST CANCER RESEARCH AND TREATMENT

Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages

(2018) Marie Febvre-James et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

(2018) Herbert Hurwitz et al.   INVESTIGATIONAL NEW DRUGS

Role of C-Reactive Protein at Sites of Inflammation and Infection

(2018) Nicola R. Sproston et al.   Frontiers in Immunology

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

(2018) Nikolas von Bubnoff et al.   BMC CANCER

Off-Target Effects of BCR-ABL and JAK2 Inhibitors

(2016) Myke R. Green et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice

(2016) Sophia Maschalidi et al.   BLOOD

Inhibition of the JAK/STAT pathway by ruxolitinib ameliorates thioacetamide-induced hepatotoxicity

(2016) Mohamed E. Shaker et al.   FOOD AND CHEMICAL TOXICOLOGY

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

(2016) S. Verstovsek et al.   HAEMATOLOGICA

The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK

(2016) J Rudolph et al.   LEUKEMIA

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

(2016) S. Verstovsek et al.   HAEMATOLOGICA

JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms

(2015) Sowmya Parampalli Yajnanarayana et al.   BRITISH JOURNAL OF HAEMATOLOGY

JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms

(2015) Kathrin Schönberg et al.   CANCER RESEARCH

Expression and functionality of Toll- and RIG-like receptors in HepaRG cells

(2015) Souphalone Luangsay et al.   JOURNAL OF HEPATOLOGY

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

(2015) Alessandro M. Vannucchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms

(2014) Sara H. Hazem et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Dissociation of Pentameric to Monomeric C-Reactive Protein Localizes and Aggravates Inflammation

(2014) Jan R. Thiele et al.   CIRCULATION

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

(2013) Srdan Verstovsek et al.   CANCER

Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

(2013) T Zhou et al.   LEUKEMIA

Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells

(2013) Marc Le Vee et al.   TOXICOLOGY IN VITRO

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

(2012) J. Mascarenhas et al.   CURRENT MEDICINAL CHEMISTRY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

C-reactive protein: How conformational changes influence inflammatory properties

(2011) Steffen U. Eisenhardt et al.   CELL CYCLE

Monomeric C-reactive protein modulates classic complement activation on necrotic cells

(2011) Michael Mihlan et al.   FASEB JOURNAL

The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers

(2011) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Catecholamines induce an inflammatory response in human hepatocytes

(2009) Caroline Aninat et al.   CRITICAL CARE MEDICINE

Inflammatory Pathways in Liver Homeostasis and Liver Injury

(2008) Frank Tacke et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Regulation of Drug Transporter Expression in Human Hepatocytes Exposed to the Proinflammatory Cytokines Tumor Necrosis Factor-  or Interleukin-6

(2008) M. L. Vee et al.   DRUG METABOLISM AND DISPOSITION